NEW YORK (GenomeWeb) – Janssen Diagnostics is now offering next-generation sequencing cancer panels from Asuragen to its research customers, expanding its services in rare cell detection, the company said today.

Under an agreement with Asuragen, Janssen is offering its customers Asuragen's proprietary SuraSeq panels. Asuragen launched two SuraSeq panels last year, which cover hotspot mutations in up to 17 oncogenes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.